These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 3774010)

  • 21. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
    J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
    Rudas M; Lehnert M; Huynh A; Jakesz R; Singer C; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Grill R; Stierer M; Gnant MF; Filipits M;
    Clin Cancer Res; 2008 Mar; 14(6):1767-74. PubMed ID: 18347178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent chemotherapy and radiation for breast conservation treatment of early-stage breast cancer.
    Markiewicz DA; Fox KR; Schultz DJ; Harris EE; Haas JA; Glick JH; Solin LJ
    Cancer J Sci Am; 1998; 4(3):185-93. PubMed ID: 9612601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant therapy for breast cancer patients with negative lymph nodes.
    Friedman MA; Dorr FA; Perloff M
    NCI Monogr; 1986; (1):139-44. PubMed ID: 3534587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Testing "the soft option": trials of adjuvant endocrine therapy for the primary treatment of breast cancer.
    Ebbs SR; Baum M
    Isr J Med Sci; 1988; 24(9-10):552-6. PubMed ID: 3060445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duration of therapy in adjuvant chemotherapy trials.
    Henderson IC; Gelman RS; Harris JR; Canellos GP
    NCI Monogr; 1986; (1):95-8. PubMed ID: 3534596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Adjuvant therapy of breast cancer patients].
    Semiglazov VF; Bavli IaL; Moiseenko VM
    Vopr Onkol; 1986; 32(11):59-63. PubMed ID: 3097961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of Canadian trials of adjuvant endocrine therapy for breast cancer.
    Meakin JW
    NCI Monogr; 1986; (1):111-3. PubMed ID: 3534582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant chemo-endocrine therapy in postmenopausal women with breast cancer and axillary-node metastases.
    Goldhirsch A; Castiglione M; Gelber RD
    Lancet; 1990 May; 335(8697):1099-100. PubMed ID: 1970400
    [No Abstract]   [Full Text] [Related]  

  • 30. The Cancer Research Campaign trials of adjuvant therapy for early breast cancer.
    Baum M; Ebbs SR; Houghton J; A'Hern RP; Riley D
    Acta Oncol; 1989; 28(6):907-12. PubMed ID: 2692654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advances breast cancer undergoing oophorectomy: a later analysis.
    Ahmann DL; Green SJ; Bisel HF; Ingle JN; Hahn RG; Lee RA; Edmonson JH
    Am J Clin Oncol; 1982 Aug; 5(4):355-8. PubMed ID: 7051804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A breast cancer Nutrition Adjuvant Study (NAS): protocol design and initial patient adherence.
    Chlebowski RT; Nixon DW; Blackburn GL; Jochimsen P; Scanlon EF; Insull W; Buzzard IM; Elashoff R; Butrum R; Wynder EL
    Breast Cancer Res Treat; 1987 Oct; 10(1):21-9. PubMed ID: 3318957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accelerated genetic destabilization and dormancy: two distinct causes of resistance in metastatic cells; clinical magnitude, therapeutic approaches.
    Israel L
    Clin Exp Metastasis; 1990; 8(1):1-11. PubMed ID: 2403488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience.
    Fisher B; Redmond C; Fisher ER; Wolmark N
    NCI Monogr; 1986; (1):35-43. PubMed ID: 3534589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
    J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of adjuvant trials in breast cancer.
    Zelen M; Gelman R
    NCI Monogr; 1986; (1):11-7. PubMed ID: 3774010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A; Gelber R
    NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.